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The aim of the present study was the evaluation and automation of the radiosynthesis of [11C]harmine
for clinical trials. The following parameters have been investigated: amount of base, precursor con-
centration, solvent, reaction temperature and time. The optimum reaction conditions were determined
to be 2–3 mg/mL precursor activated with 1 eq. 5 M NaOH in DMSO, 80 °C reaction temperature and
2 min reaction time. Under these conditions 6.171 GBq (51.0711% based on [11C]CH3I, corrected for
decay) of [11C]harmine (n¼72) were obtained. The speciﬁc activity was 101.32728.2 GBq/mmol (at EOS).
All quality control parameters were in accordance with the standards for parenteral human application.
Due to its reliability and high yields, this fully-automated synthesis method can be used as routine set-
up.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Monoamine oxidases (MAO) are primarily located in the outer
mitochondrial membrane of catecholaminergic neurons where
they are responsible for the degradation of monoamine neuro-
transmitters (Weyler et al., 1990). Two subtypes of the enzyme,
MAO-A and MAO-B, have been identiﬁed on the basis of their
substrate selectivity, biochemical properties and gene products
(Johnston, 1968; Shih et al., 1999). MAO-A preferentially oxidizes
serotonin, norepinephrine and epinephrine and is therefore an
attractive target in the study of psychiatric and neurological dis-
eases. Highly elevated levels of MAO-A in the human brain are
associated with major depression disorder (Meyer et al., 2006),Ltd. This is an open access article u
.at (W. Wadsak).whereas inhibition of MAO-A is useful in the treatment of de-
pression and anxiety disorders (Livingston and Livingston, 1996).
For the in vivo measurement of the MAO-A density the positron
emission tomography (PET) radioligands [11C]clorgyline, [11C]
clorgyline-D2 (Fowler et al., 2001), [11C]beﬂoxatone (Dollé et al.,
2003) and [11C]harmine (Bacher et al., 2011; Bergström et al.,
1997a, 1997b; Ginovart et al., 2006; Meyer et al., 2009; Sacher
et al., 2010) have been used since several years. The β-carboline
derivative [11C]harmine is a selective and reversible inhibitor of
MAO-A with high brain uptake and high afﬁnity (Ki¼5 nM) (Kim
et al., 1997).
The aim of the present study was the implementation and
automation of the radiosynthesis of [11C]harmine into our clinical
setup in order to investigate seasonal depression in a clinical trial.
We slightly modiﬁed the synthesis described by Bergström et al.
(1997a) and conducted additional evaluation steps.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Materials
All chemicals and solvents were obtained from commercial
sources with analytical grade and used without further puriﬁca-
tion. Iodine (sublimated grade for analysis; ACS, Pharm. Eur.) was
purchased from Merck (Darmstadt, Germany; product number:
1.04761.0100). The Ni catalyst (Shimalilte Ni reduced, 80/100
mesh) was purchased from Shimadzu (Kyoto, Japan). The pre-
cursor harmol (7-hydroxy-1-methyl-9H-pyrido[3,4-b]indole; GMP
grade) and the reference compound harmine (7-methoxy-1-me-
thyl-9H-[3,4-b]indole) were obtained from ABX (ABX-Advanced
Biochemical Compounds, Radeberg, Germany). Harmaline (4,9-
dihydro-7-methoxy-1-methyl-3H-pyrido[3,4-b]indole), the re-
ference compound for a potential radioactive by-product, dimethyl
sulfoxide (DMSO) (anhydrous, Z99.9%), N,N-dimethylformamide
(DMF) (puriss., Z99.8%) and acetonitrile were obtained from
Sigma Aldrich (Vienna, Austria). Ammonium formate, ammonium
acetate, acetic acid, sodium hydroxide (NaOH) and ethanol (ab-
solute) were purchased from Merck (Darmstadt, Germany). 0.9%
Saline solution was purchased from B. Braun (Melsungen, Ger-
many). 3% Saline solution was obtained from a local pharmacy
(Landesapotheke Salzburg, Austria). 125 mM phosphate buffer was
prepared by dissolving 0.224 g sodium dihydrogenphosphate-
monohydrate and 1.935 g disodiumhydrogenphosphate-dihydrate
(both from Merck, Darmstadt, Germany) in 100 mL sterile water.
Sterile water was purchased from B. Braun (Melsungen, Germany).
C18plus SepPaks cartridges for solid phase extraction (SPE) were
purchased from Waters (Waterss Associates Milford, MA, USA).
Low-protein binding Millex GSs 0.22 mm sterile ﬁlters were pur-
chased from Millipores (Bedford, MA, USA). Semipreparative high
performance liquid chromatography (HPLC) column (Supelcosil™
LC-ABZþ; 5 mm, 250 mm10 mm; Nr. 59179) was purchased
from Supelco (Bellfonte, PA, USA). Analytical HPLC-column (Prod-
igy 10 mm ODS (3); 250 mm4.6 mm; Nr. 00G-4244-E0) was
obtained from Phenomenex (Aschaffenburg, Germany).
2.2. Instrumentation
[11C]CO2 was produced at a GE PET trace cyclotron (General
Electric Medical System, Uppsala, Sweden) via the 14N(p,α)11C
nuclear reaction by irradiation of a gas target (Aluminium) ﬁlled
with N2 (þ1% O2) (Air Liquide, Vienna, Austria). Typical beam
currents were 50–56 mA and the irradiation was stopped as soon
as the desired activity level was reached (approx. 50–65 GBq [11C]
CO2, calculated by cyclotron operating software; corresponding to
20–30 min irradiation time). The production of [11C]CH4, [11C]CH3I
and [11C]harmine including semi-preparative HPLC were per-
formed on a TRACERlab™ FX C Pro synthesis module (GE
Healthcare, Uppsala, Sweden). Analytical HPLC was performed
using a Merck-Hitachi LaChrom system consisting of a L-7100
pump, a Merck-Hitachi LaChrom L7400 UV-detector (operated at
254 nm) and a lead shielded NaI-radiodetector (RaytestFig. 1. Radiosynthesis of [11C]harminIsotopenmessgeräte GmbH, Straubenhardt, Germany). The os-
molality was measured using a Wescor osmometer Vapros 5600
(Sanova Medical Systems, Vienna, Austria) and pH was measured
using a WTW inoLab 740 pH metre (WTW, Weilheim, Germany).
2.3. Radiosynthesis of [11C]harmine
2.3.1. Manually operated small scale syntheses
[11C]CH3I was produced in the TRACERlab™ FX C Pro synthesis
module using the gas phase conversion described by Larsen et al.
(1997) and trapped in 1 mL DMSO and DMF, respectively. The re-
action of [11C]harmine was started by adding a portion of the
trapped [11C]CH3I to the precursor solution (ﬁnal precursor con-
centration: 0.5–3 mg/mL), dissolved in DMSO/DMF and activated
with 0–6 equivalent (eq.) of 5 M NaOH. The reaction was con-
ducted in a 0.5 mL Wheaton-Vial. A reaction scheme is shown in
Fig. 1. Different reaction temperatures (25–100 °C) were evaluated.
After 0.5–2 min reaction time, the reaction mixture was quenched
with water and the radiochemical incorporation yield (RCIY) was
determined using analytical radio-HPLC (mobile phase: 0.1 M
ammonium formate (pH 4)/acetonitrile 75/25 v/v; ﬂow: 1.5 mL/
min). Chromatograms were registered using an UV-detector
(254 nm) and a NaI radioactivity detector in series.
2.3.2. Fully-automated large scale syntheses
2.3.2.1. Preparation of the synthesis module. A scheme of the
synthesis module is presented in Fig. 2. All parts prior to HPLC-
puriﬁcation (reactor, HPLC injector, tubing) were rinsed with water
and acetone and then dried with a stream of helium. Parts after
preparative HPLC (i.e. SPE tubing, dilution ﬂask, product collection
vial, product outlet tubing) were cleaned using ethanol and phy-
siological saline (0.9%).
Vessels were ﬁlled as followed:
Vial 2: 0.5 mL of HPLC eluent (0.1 M ammonium acetate and
acetonitrile (60/40; v/v)) for quenching of the reaction and
dilution prior to HPLC injection;
Vial 4: 5 mL of physiological saline (0.9%) for ﬁnal rinsing of the
SPE cartridge and dilution of the eluate;
Vial 5: 1.5 mL of ethanol for elution of the SPE cartridge;
Vial 6: 10 mL of sterile water for washing the SPE cartridge;
Vials 1 & 3 remained empty and were not used for the
synthesis;
Bulb: 60 mL of sterile water for dilution of the lipophilic HPLC
fraction after peak cutting.
A C18 SPE cartridge was preconditioned using 5 mL of ethanol
and 10 mL of sterile water, dried and connected to its designated
position. The product collection vial (PCV) was ﬁlled with 4 mL of
physiological saline (0.9%), 1 mL of 3% saline and 1 mL of phos-
phate buffer (125 mM). The reactor was ﬁlled with 1–1.5 mg har-
mol and 1 eq. of 5 M NaOH dissolved in 0.5 mL of DMSO. Subse-
quently the reactor was placed into the heating block.e (i: H2/Ni, 400 °C; ii: I2, 734 °C).
Fig. 2. Scheme of the commercial 11C-synthesizer used for the radiosynthesis and puriﬁcation of [11C]harmine (SPE: solid phase extraction; PCV: product collection vial). For
details in set-up and processing refer to Section 2.3.2.
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of [11C]harmine was performed on the prepared radiosynthesizer.
[11C]CH3I was bubbled through the precursor solution at room
temperature. The reactor was sealed and the reaction mixture
heated to 80 °C and kept at this temperature for 2 min. AfterFig. 3. Semi-preparative chromatogram of the reaction solution ofcooling down to room temperature (o1 min), the reaction mix-
ture was quenched by addition of 0.5 mL of HPLC-eluent (through
V2) and subsequently transferred to the 5 mL injection loop of the
HPLC-system by passing the ﬂuid detector.[11C]harmine (top: UV cannel; bottom: radioactivity channel).
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the crude reaction mixture to the semi-preparative RP-HPLC column
was controlled by an automated ﬂuid detector. Semi-preparative
HPLC was performed with 0.1 M ammonium acetate and acetonitrile
(60/40; v/v) as a mobile phase with an isocratic ﬂow of 8 mL/min.
Chromatograms (Fig. 3) were registered using an UV-detector
(254 nm) and a NaI radioactivity detector in series. The [11C]harmine
fraction was cut into a bulb (containing 60 mL of sterile water)
through V14. The resulting solution was then pushed through a C18
SPE cartridge. After washing with 10 mL of water (Vial 6) the puriﬁed
product was completely eluted with 1.5 mL of ethanol (Vial 5) and
5 mL of 0.9% saline (Vial 4). Formulation was done with a further
4 mL of physiological saline (0.9%), 1 mL of saline solution (3%) and
1 mL of phosphate buffer (125 mM) in the product collection vial.
This ﬁnal solution was transferred to a shielded laminar air-ﬂow hot
cell and, there, sterile-ﬁltered (0.22 mm) into a sterile 25 mL vial
containing another 5 mL of saline solution 0.9%. Hence, the ﬁnal total
volume was 17.5 mL (containing 8.5% ethanol).
2.3.2.4. Quality control of [11C]harmine. Chemical and radio-
chemical impurities were detected and quantiﬁed using analytical
radio-HPLC (for conditions see Section 2.3.1), according to the
monograph in the European Pharmacopoeia (2008). The whole
HPLC analysis was completed within 7 min, the retention time of
the precursor (harmol) was 3.1–3.3 min (kʹ¼0.4–0.5), harmaline
was eluted with a retention time of 5.2–5.5 min (kʹ¼1.3–1.5) and
the product [11C]harmine was eluted at 5.5–6.4 min (kʹ¼1.5–1.9).
The chemical identity of [11C]harmine was determined by co-in-
jection of the unlabelled reference compound harmine. For cal-
culation of radiochemical purity, the portion of [11C]harmine in
relation to total radioactivity was determined (threshold Z95%).
Sample chromatograms are given in Fig. 4.
Osmolality and pH were determined to assure safe adminis-
tration using standard methods. Radionuclidic purity was assessed
by recording of the corresponding gamma spectrum and addi-
tional measurement of the physical half-life.Fig. 4. Typical chromatogram of the puriﬁed and formulated [11C]harmineTesting of sterility and concentration of bacterial endotoxins
was performed using standard protocols at the Department of
Infection Diseases and Tropical Medicine (Medical University of
Vienna, Austria).
2.4. Statistical analysis
All values are given by arithmetic means7standard deviation.
To determine signiﬁcant differences a two-tailed t-test with
α¼0.95 was performed using the statistics add-on in Microsofts
Excel. A value of Po0.05 was considered as signiﬁcant.3. Results and discussion
3.1. Small scale syntheses
Following parameters were investigated: amount of 5 M NaOH,
precursor concentration, solvent, reaction temperature and time.
The sample size was Z2.
Using 1 mg/mL precursor in DMSO and 2 min reaction time, the
added amount of 5 M NaOH had a high impact on the RCIY. The
highest yields could be achieved using 1 eq. of 5 M NaOH:
73.55718.7% at 25 °C, 86.0575.1% at 50 °C and 84.8672.2% at
80 °C. Using 6 eq. of 5 M NaOH resulted in a signiﬁcantly lower
yield: 14.5772.0% at 25 °C, 20.4474.9% at 50 °C and 29.6570.0%
at 80 °C. Almost no conversion could be observed conducting the
synthesis without 5 M NaOH (Fig. 5A).
A clear trend was observed between the RCIY and the precursor
concentration (experiments conducted in DMSO at 80° and for
2 min). RCIY increased signiﬁcantly with increasing precursor
amount. The highest RCIY was obtained using 3 mg/mL precursor
(84.0972.0%); 72.3771.2% using 2 mg/mL, 62.4071.1% using
1 mg/mL and 56.5770.2% using 0.5 mg/mL (Fig. 5B).
The reaction temperature had no signiﬁcant impact on the RCIY
but a greater variance could be observed at 25 °C (Fig. 5C;using analytical HPLC (top: UV cannel; bottom: radioactivity channel).
Fig. 5. Dependence pf the radiochemical incorporation yield (RCIY) of [11C]harmine (nZ2) on (A) amount of 5 M NaOH (@ 1 mg/mL precursor, 2 min), (B) precursor
concentration (@ 80 °C, 2 min), (C) reaction temperature (@ 2 mg/mL precursor, 2 min) and (D) reaction time (@ 2 mg/mL precursor, 25 °C). If not visible, error bars are
within the margin of the symbols.
Table 1
Optimum reaction conditions and outcome for
large scale preparations of [11C]harmine (n¼72).
Reaction temperature (°C) 80
Reaction time (min) 2
Amount of precursor (mg/mL) 2–3
Solvent DMSO
Yield (GBq)a 6.171
Yield (%)b 51.0711
Speciﬁc activity (GBq/mmol)a 101.3728
Radiochemical purity (%) 10070
a At end of synthesis (EOS).
b Based on [11C]CH3I, corrected for decay.
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2 min). This temperature was favourable for the formation of the
by-product [11C]harmaline reducing the radiochemical purity of
the product.
Regarding the reaction time, 74.32719.2% RCIY were already
achieved after 0.5 min; 57.35723.8 after 1 min and 68.24722.7
after 2 min (Fig. 5D; experiments conducted in DMSO with
2 mg/mL precursor at 25 °C). There was no signiﬁcant difference in
the RCIYs between the reaction times.
Changing the solvent from DMSO to DMF resulted in a sig-
niﬁcantly lower RCIY. Using 1 mg/mL precursor, 80 °C reaction
temperature and 2 min reaction time the RCIY was 24.63713.7%
in DMF and 56.5770.2% in DMSO.
Hence, the optimum reaction conditions were determined and
summarized in Table 1.
3.2. Fully-automated large scale syntheses
The fully-automated synthesis and puriﬁcation of [11C]harmine
was performed successfully and with high reliability within
35 min after the end of bombardment (EOB). In 72 runs
6.171 GBq (51.0711% based on [11C]CH3I trapped on the [11C]
CH3I-Trap, corrected for decay) of [11C]harmine were obtained
under the optimum reaction conditions (Table 1) as a sterile so-
lution ready for application. 4 Syntheses failed due to technical
problems. Typical loss during sterile ﬁltration was o10% of the
product activity. The radiochemical purity was in every synthesis
100% as determined by radio-HPLC. The precursor concentration inthe ﬁnal product ranged from 0 to 2.66 mg/mL (0.3471.5 mg/mL)
and the speciﬁc activity was 101.32728.2 GBq/mmol
(0.7570.3 mg/mL harmine) at the end of synthesis (EOS). Sample
chromatograms are shown in Fig. 4. Osmolality was
292711 mosmol/kg and pH was 7.570.1. Concentration of en-
dotoxins was found to be below 1.0 EU/mL and all samples passed
the test for sterility. Concluding, all quality control parameters
were in accordance with the standards for parenteral human ap-
plication. The quality control (except tests for endotoxins and
sterility) was completed within 7 min.
Compared to the radiochemical yields (72.573.6% based on
[11C]CH3I, corrected for decay) in the synthesis described by
Bergström et al. (1997a), in our set-up, we obtained lower yields
(51.0711%) with the same parameters (DMSO, 1 eq. 5 M NaOH
C. Philippe et al. / Applied Radiation and Isotopes 97 (2015) 182–187 187and 80 °C) but using a lower precursor concentration (2 mg/mL
compared to 3.3–6.6 mg/mL) and shorter reaction time (2 min
compared to 5 min). We also achieved higher speciﬁc activities
(101.32728.2 GBq/mmol compared to 18.0–87.3 GBq/mmol) which
is of advantage for clinical trials.4. Conclusion
We established a rapid, reproducible and reliable preparation
and puriﬁcation method on a commercially available synthesis
module. The optimum reaction conditions were 2–3 mg/mL pre-
cursor activated with 1 eq. 5 M NaOH in DMSO, 80 °C reaction
temperature and 2 min reaction time. Due to its reliability and
high yields (6.171 GBq), the presented method can be used as
routine set-up.Acknowledgement
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